NAMD
Clinical trials for NAMD explained in plain language.
Never miss a new study
Get alerted when new NAMD trials appear
Sign up with your email to follow new studies for NAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy aims to free patients from monthly eye injections
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help the eye make its own medicine to control the disease, potentially redu…
Matched conditions: NAMD
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 22:47 UTC
-
New shot in the eye aims to halt leading cause of blindness
Disease control Recruiting nowThis study is testing a new drug called SCT520FF, given as an injection into the eye, for people with 'wet' age-related macular degeneration (AMD). The main goals are to find a safe dose and see if it helps improve or stabilize vision. Researchers will enroll about 82 patients to…
Matched conditions: NAMD
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Eye implant could replace monthly injections for blinding disease
Disease control Recruiting nowThis study is testing a small, refillable implant placed in the eye that slowly releases a medicine (ranibizumab) for six months. It is being compared to the standard treatment of receiving the same medicine as a monthly injection into the eye. The goal is to see if the implant w…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
One-Shot gene therapy could end decades of eye injections for millions
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help control the disease long-term, potentially freeing patients from the b…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC